Skip Navigation


NDT Advance Access originally published online on September 6, 2006
Nephrology Dialysis Transplantation 2006 21(10):2684-2686; doi:10.1093/ndt/gfl460
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/10/2684    most recent
gfl460v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in NDT
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bargman, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bargman, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Peritoneal dialysis solutions and patient survival: does wishing make it so?

Joanne M. Bargman

Department of Medicine, Division of Nephrology, University of Toronto, Canada

Correspondence and offprint requests to: Joanne M. Bargman, MD, FRCPC, Department of Medicine, Division of Nephrology, University Health Network, 200 Elizabeth Street 8N-840, Toronto, Canada M5G 2C4. Email: joanne.bargman@uhn.on.ca

Keywords: patient survival; PD; PD solutions; residual renal function

The first 10% of the full text of this article appears below.

In this issue of Nephrology, Dialysis and Transplantation, Lee and colleagues [1] compare outcomes of Korean peritoneal dialysis (PD) patients who received standard dialysis fluid vs newer, ‘biocompatible’dialysis solutions. This very interesting report found no significant difference in outcome of PD technique survival or its complications, such as peritonitis. However, those who received the new solution had a reduced risk of death. The authors suggest that the newer dialysis solutions may lead to sustained reduction in circulating levels of advanced glycosylation endproducts (AGEs), with a concomitant reduction in microvascular and macrovascular disease. Furthermore, the authors point to downstream effects of AGE binding with its receptors (RAGE), and suggest that reduced AGE production with new solutions could be followed by a parallel decline in the AGE–RAGE production of mediators of inflammation and fibrosis.

The authors . . . [Full Text of this Article]



   Who gets the expensive stuff?
 


   How could new dialysis solutions improve survival?
 
Residual kidney function
Reduction in GDP absorption and systemic glycation


   Wishing doesn't make it so
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in NDT:

Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome
Ho Yung Lee, Hoon Young Choi, Hyeong Cheon Park, Bo Jeung Seo, Jun Young Do, Sung Ro Yun, Hyun Yong Song, Yeong Hoon Kim, Yong-Lim Kim, Dae Joong Kim, Yong Soo Kim, Moon Jae Kim, and Sug Kyun Shin
NDT 2006 21: 2893-2899. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 CJASNHome page
J. M. Bargman
New Technologies in Peritoneal Dialysis
Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 576 - 580.
[Abstract] [Full Text] [PDF]